Skip to main content
Molimo sačekajte...

REMISIJA DIABETES MELLITUSA TIPA 2 KOD GOJAZNIH PACIJENATA

E-mail
natasa.neskovic977@gmail.com
djenic.cigota@gmail.com
Ustanova
Zdravstveni centar Užice
Specijalna bolnica za bolesti štitaste žlezde i bolesti metabolizma Zlatibor
Reference
Marathe PH, Gao HX, Close KL. American Diabetes Association Standards of Medical Care in Diabetes 2017. Journal of diabetes. 2017; 9(4): 320–24.
Tangelloju S, Little BB, Esterhay RJ, Brock G, LaJoie AS. Type 2 Diabetes Mellitus (T2DM) “Remission” in Non-bariatric Patients 65 Years and Older. Front Public Health. 2019; 12(7): 82.
Buse JB, Caprio S, Cefalu WT, Ceriello A, Del Prato S, Inzucchi SE et al. How do we define cure of diabetes? Diabetes care. 2009; 32(11): 2133–35.
Sažetak

REMISIJA DIABETES MELLITUSA TIPA 2 KOD GOJAZNIH PACIJENATA

Medicinski glasnik

Inhibitor natrijum-glukoznog kotransportera tipa 2 – dapagliflozin u terapiji obolelih od diabetes mellitus tipa 2

E-mail
djenic.cigota@gmail.com
Ustanova
Zdravstveni centar Užice
Specijalna bolnica za bolesti štitaste žlezde i bolesti metabolizma Zlatibor
Reference
Đukić A, Đurđević P, Živančević-Simonović S, Jurišić V, Mijatović Lj. Opšta patološka fiziologija. Beograd; Intergraf: 2002; 400–408.
International Diabetes Federation. IDF Diabetes Atlas, 7th ed. International Diabetes Federation: Brussels, Belgium: 2015; available at: http://www.diabetesatlas.org
Stark Casagrande, S., Fradkin, J., Saydah, S., Rust, K. and Cowie, C. (2013) The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988–2010. Diabetes Care 36: 2271–2279.
Sažetak

Inhibitor natrijum-glukoznog kotransportera tipa 2 – dapagliflozin u terapiji obolelih od diabetes mellitus tipa 2

Medicinski glasnik